Welcome to our dedicated page for MARAVAI LIFESCIENCES HOLDINGS SEC filings (Ticker: MRVI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Maravai LifeSciences Holdings, Inc. filings document the formal disclosures of a Nasdaq-listed life sciences operating company with Class A common stock. Form 8-K reports furnish quarterly and annual financial results, including revenue, net loss, adjusted EBITDA and business updates for the TriLink nucleic acid synthesis and Cygnus biologics safety testing operations.
The company’s proxy materials describe annual meeting matters, director elections, independent auditor ratification, executive compensation votes and board governance. Other current reports record leadership succession, board-size and committee changes, equity-award treatment, and restructuring actions classified as exit or disposal activities, including related cost disclosures and risk language.
Form 4 filed for Maravai LifeSciences Holdings, Inc. (MRVI) discloses that director Jessica Hopfield received 89,139 Class A common-stock restricted stock units (RSUs) on 16 June 2025 under the company’s 2020 Omnibus Incentive Plan. The RSUs will vest in full on the earlier of one year from the grant date or the 2026 annual stockholders’ meeting. Following the award, Hopfield now reports 199,907 shares held directly. Transaction code “A” confirms the award was an acquisition, not an open-market purchase or sale. No derivative securities were involved, and there were no dispositions. Overall, the filing represents a routine equity incentive grant aligning director compensation with shareholder interests.